Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1450)	10/20/1998 5:26:00 PM
From: yosi s	Respond to of 1491

The last cohort of the phase 2 trial is split 2:1 In a sense they have lots of placebo patients. By safely increasing the active part, without jeoperdizing the control of a placebo group. Enable to get most information out of treatment group. This may even get greater significance , and better planning for phase 3.

To: Rick Strange who wrote (1450)	10/20/1998 9:37:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

Rick, I thought the split was not 50-50 and that's why more are getting dex in the third cohort. First two cohorts of Phase II: dex -- 30 patients..........placebo -- 37 patients If 20 more are added for part 3, Phase II: dex ~ 13 patients.........placebo ~ 7 patients Total for all three (87 patients): dex ~ 43 patients..........placebo ~ 44 patients ----------------------------------------------------------------------- If 30 patients are added for part 3: dex ~ 20 patients............placebo ~ 10 patients Total for all three (97 patients): dex ~ 50 patients.............placebo ~ 47 patients I just figured we needed more headcount on the dex side (and, by the way, why didn't it come out roughly 50-50 to begin with?). -Ariella